Created On: 2020-07-15
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7592
Long-acting ÃŸ2 adrenoceptor agonist or LABA means a chemical entity that selectively binds to human ÃŸ2 adrenoceptors and activates certain human ÃŸ2 adrenoceptors.
API compound means bulk quantities of active pharmaceutical ingredient compound prior to the commencement of secondary manufacturing resulting in a collaboration product.
IPSCIO Record ID: 6473
IPSCIO Record ID: 203286
– a worldwide, nonexclusive, non-transferable license under the Licensors IP and interest in the Collaboration IP, to research such Specified Compound(s) and such Product(s) for applications in the Field;
– a worldwide, exclusive, royalty-bearing, non-transferable license, with the right to sublicense, under the Licensors IP and interest in the Collaboration IP, to develop, make, have made, and use such Specified Compound(s) and Product(s) in the Field; and
– a worldwide, exclusive, royalty-bearing, non-transferable license, with the right to sublicense, under the Licensors IP and interest in the Collaboration IP, to promote, market, distribute, sell, offer to sell, import, and otherwise commercialize Product(s) in the Field.
EPI-A0001 has received orphan drug status in the treatment of inherited mitochondrial respiratory chain diseases.
The mitochondrial respiratory chain has the crucial function of supplying the cell with energy in the form of ATP. Mutations affecting this chain can arise in mitochondrial or nuclear DNA and cause diseases known as mitochondrial encephalomyopathies. Because the rules of inheritance of mitochondrial and nuclear DNA differ considerably, these brainâ€“muscle syndromes often have unpredictable clinical and genetic features.
The Field shall mean the treatment or prophylaxis of all diseases and conditions in humans including all indications in the Non-Orphan Field and the Target Field. The Target Field shall mean the treatment of inherited mitochondrial diseases of the cellular respiratory chain that satisfy the FDAâ€™s requirements for orphan product designation.